Clinical Trial Detail

NCT ID NCT02970539
Title Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kinex Pharmaceuticals Inc
Indications

esophageal cancer

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Oraxol + Ramucirumab

Age Groups: adult senior

No variant requirements are available.